Therapeutic activity does not respect kingdom boundaries. NeuroBotanica™ models, predicts, and validates cross-kingdom molecular interactions computationally — before any laboratory synthesis.
Polysaccharides from marine organisms, fungal cell walls, and plant mucilages share structural and immunological properties that interact synergistically with cannabinoids, terpenes, and alkaloids. No competitor has modeled this interaction space computationally.
Our platform is built to model, predict, and validate these cross-kingdom interactions using a proprietary AI prediction model — generating novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential.
This is a predictive systems biology approach, not a chemical lookup table.
Cannabis is the active, evidence-backed research base today. The platform's cross-kingdom architecture is built to extend to marine, fungal, and plant polysaccharide research as that evidence base grows.
THC, CBD, CBN, CBG, CBDV and 12 additional cannabinoids + 4 active metabolites. 16 neuropsychiatric conditions, pain, epilepsy, oncology support.
Fucoidan, carrageenan, ulvan from seaweed. The cross-kingdom architecture is built to extend to this immunomodulation and anti-inflammatory research as it's incorporated.
Beta-glucans, hericenones, cordycepin, lentinan. Built to extend to this neuroprotective and immune-enhancement research.
Galactomannans, rhamnogalacturonans, pectins. Built to extend to this research as the evidence base grows.
Our proprietary AI prediction model forecasts molecular interactions across compound classes. Predicts synergy before synthesis.
Generates novel molecular combinations with formation probability, synergy scores, and condition-specific therapeutic potential across all four kingdoms.
The traditional knowledge integration layer integrates validated traditional knowledge into compound discovery pathways. FPIC-governed, consent-logged, and attribution-tracked via VeriTrad™.
EquiPath™ integration detects and corrects demographic bias in all predictions. 96% accuracy. Ensures recommendations work across populations — not just overrepresented groups.
The regulatory pathway mapping layer maps each compound to FDA and DSHEA pathways. GRAS notifications, NDI submissions, clinical trial design — regulatory readiness built into the platform.
Every recommendation is ranked by evidence quality — meta-analysis, RCT, cohort, in vitro, traditional use. Transparent, reproducible, auditable at every step.
Dispensaries, researchers, academic institutions, and community organizations. There is a structured partnership pathway for each.